Use access key #2 to skip to page content.


No Lucky Charms earned yet.

InMed Pharmaceuticals: Moving Medical Cannabis Forward On Multiple Fronts



July 10, 2017 – Comments (0) | RELATED TICKERS: IMLFF

Medical cannabis as an industry continues to evolve in ways that have shown more promise than most expected even a few short years ago.  A changing approach to science has been matched by widespread legislative approvals where we now see the legalization of medical cannabis treatments in 29 states and in Washington, D.C. itself.  

For investors, this means that there is still an opportunity to get in on the ground floor and gain stock exposure in a vastly growing industry.  But it is still important to understand which companies are leading the pack in terms of strategy and innovation in the treatment of patients.  Those able to properly identify these innovators will reap long-term rewards as these bullish trends continue to gain traction.   

Biosynthesis Innovation

One industry standout that continues to make headlines is InMed Pharmaceuticals, Inc. (OTCMKTS: IMLFF), which is a Vancouver-based preclinical stage biopharmaceutical company that has designed a unique low-cost, high-yield biosynthesis approach to cannabinoid development. 

Historically, most companies in the sector have struggled with the development of cannabinoid-based therapeutics.  For the most part, the focus typically lies in isolating tetrahydrocannabinol (THC) and cannabidiol (CBD) because they are both relatively easy to extract from the marijuana plant.  

But InMed Pharmaceuticals has taken this process a step further.  The reality is that 90+ other cannabinoids exist in every marijuana plant -- and InMed’s biosynthesis manufacturing technology has proven itself to be a gamechanger in unlocking their potential benefits in ways that are cost-effective, safe, and scalably produced in a laboratory setting.  

Design and Process

Essentially, InMed’s process starts by isolating the genes in the cannabis plant that are responsible for producing specific cannabinoid compounds. Next, these genes are injected into a bacteria that acts as a factory for producing those cannabinoids at scale. These compounds are then combined to create unique therapies that target diseases which have previously proven to be resistant to most other treatments.  This is breakthrough technology that could unlock the potential for hundreds of clinical programs, and investors here stand to benefit from a CBD market that is expected to surpass $2 billion by 2020.

In the current market context, InMed is devoting significant resources to testing treatments for Epidermolysis Bullosa (EB) and Glaucoma with specific cannabinoid compounds.  EB is a group of devastating, inherited connective tissue diseases with no approved treatments -- and this market void could pave the way for faster regulatory approvals.

Glaucoma is the second leading cause of blindness in the developed world.  Initial estimates show that the global market for a successful EB therapy could be worth upwards of $1 billion per year.  InMed’s Glaucoma program, INM-085, targets an even larger global market that is already worth over $5.6 billion annually (with 2.7 million patients located in the United States alone).  Individually, each of these uses of InMed products indicates the potential for substantial value for investors in the company.

Strategy Development

InMed’s promising technological developments and product pipelines are attractive on their own.  But it is clear that the company is still looking to push its businesses further.  Recent additions to InMed’s Scientific Advisory Board include Dr. Mauro Macarrone, Professor and Chair of Biochemistry and Molecular Biology at Campus Bio-Medico University of Rome and Director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-Santa Lucia Foundation.  

Strategy development contributions from these types of high-caliber industry leaders support the outlook for InMed Pharmaceuticals, which is constantly evolving to meet the needs of patients.  InMed’s proprietary bioinformatics database assessment tool, its biosynthesis manufacturing process, and its drug development programs are fundamental value drivers for the company and factors that should continue supporting revenue performances over the next several years.

Investors that are looking to gain exposure in the up-and-coming medical cannabis industry will need to assess companies based on their merits, proven track records, and the ability to adapt to a changing market environment.  By all accounts, we are still in the early phases of development for the sector.  But it is still possible to identify solid companies that are already positioned to guide the industry through strategy and innovation.  InMed Pharmaceuticals will continue to be one name to watch, as we are already seeing their influence felt in many important areas within the modern biotechnology framework.  

0 Comments – Post Your Own

Blog Archive

January (1)
September (2) July (2)

Featured Broker Partners